Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
Prostate cancer has proved an elusive target for cancer immunotherapies, and Merck & Co's checkpoint inhibitor Keytruda is the ... or radiographic progression-free survival (rPFS) when the data ...
The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...
Merck & Co reported stronger-than-expected quarterly earnings thanks to rising Keytruda sales. However, Gardasil's weak ...
Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...
Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.
Merck Research Laboratories. "These approvals underscore the continued expansion of the use of KEYTRUDA in diverse patient populations and treatment settings with utility of KEYTRUDA ranging from ...
Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with ...
Merck reported third-quarter revenue and adjusted earnings that topped expectations. The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback